Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment

Bradley Schwartz, DO; Daniel S. Schwartz, MD


June 27, 2022

In the phase 3 STAMPEDE trial, the addition of the anti-androgen therapy abiraterone plus the steroid prednisolone to ADT resulted in improved overall survival in patients with mHSPC not previously treated with hormone therapy, as well as improved rates of treatment failure–free survival.

Similarly, the phase 3 ENZAMET trial showed that adding the anti-androgen therapy enzalutamide to ADT resulted in longer survival in patients with mHSPC. The phase 3 ARCHES trial also investigated the addition of abiraterone acetate to ADT in patients with mHSPC. Interim analysis data showed improved radiographic progression-free survival with the addition of enzalutamide, which was consistent across all prespecified subgroups, including disease volume and prior docetaxel chemotherapy. Survival data were not yet mature at the time of analysis.

Intermittent ADT plus chemotherapy continues to be investigated in patients with metastatic prostate cancer. So far, significant improvements in quality of life with use of this treatment method have been noted, including fewer issues with libido and potency.

Learn more about new and emerging treatment options for patients with mHSPC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.